ATBECHDEDKESFR..GRITLILUNLSE..PTIESILTLVFIROMKCYAL..............................JDIM360 (Ver 1.5 21 Nov 2005) - 2999001/0 2600000/0The file contains technical information submitted after the application was filed and not included in this specification1175904CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120070509W184deBibliographieenBibliographyfrBibliographieEP01201913.9199807172003061820031126enenen53351 P19970722US53535 P19970723US971759019970820GB971785019970822GB2007050920071920020130200205200703282007132006121820070509200719A61K 31/663 20060101AFI20021030BHEP A61P 19/10 20060101ALI20021030BHEP deAlendronate zur Behandlung von OsteoporoseenAlendronate for use in the treatment of osteoporosisfrL'alendronate destiné à être utilisé dans le traitment de l'ostéoporoseEP-A1- 0 274 158WO-A1-94/00129WO-A1-95/08331WO-A1-95/28936SINGER F R ET AL: "Bisphosphonates in the treatment of disorders of mineral metabolism." ADVANCES IN ENDOCRINOLOGY AND METABOLISM, (1995) 6 259-88. REF: 109 JOURNAL CODE: CB4. ISSN: 1049-6734., XP002092145 United StatesLIBERMAN U A ET AL: "EFFECT OF ORAL ALENDRONATE ON BONE MINERAL DENSITY AND THE INCIDENCE OF FRACTURES IN POSTMENOPAUSAL OSTEOPOROSIS" THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 333, no. 22, 30 November 1995 (1995-11-30), pages 1437-1443, XP000579307BANKHURST A ET AL: "THREE-YEAR TREATMENT WITH ALENDRONATE PREVENTS FRACTURES IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS" ARTHRITIS AND RHEUMATISM, vol. 38, no. 9, SUPPL, 1 September 1995 (1995-09-01), page S359 XP000579368FILIPPONI P ET AL: "CYCLICAL CLODRONATE IS EFFECTIVE IN PREVENTING POSTMENOPAUSAL BONE LOSS: A COMPARATIVE STUDY WITH TRANSCUTANEOUS HORMONE REPLACEMENT THERAPY" JOURNAL OF BONE AND MINERAL RESEARCH, vol. 10, no. 5, May 1995 (1995-05), pages 697-703, XP002042531MCCLUNG M R ET AL: "Tiludronate therapy for Paget's disease of bone [published erratum appears in Bone 1996 Mar;18(3):292]." BONE, (1995 NOV) 17 (5 SUPPL) 493S-496S. JOURNAL CODE: ASR. ISSN: 8756-3282., XP002092146 United StatesSELTENMEYER, Y. ET AL: "A comparison of the antiresorptive potency of various bisphosphonates in vivo with their inhibitory effect in vitro on squalene synthase and cellular sterol synthesis." BONE (NEW YORK), (1997) VOL. 20, NO. 4 SUPPL., PP. 114S. MEETING INFO.: 25TH EUROPEAN SYMPOSIUM ON CALCIFIED TISSUES HARROGATE, ENGLAND, UK APRIL 25-29, 1997 ISSN: 8756-3282., XP002092147ADACHI J.D.: "osteoporosis-Its Diagnosis, Management and Treatment with New Oral Bisphophonate Agent, Etidronate" TODAY'S THERPAEUTIC TRENDS, vol. 14, no. 1, 1996, pages 13-24, XP002092148BELL, NORMAN H. ET AL: "Bisphosphonates in the treatment of osteoporosis" ENDOCRINE (1997), 6(2), 203-206 CODEN: EOCRE5;ISSN: 1355-008X, XP002092149 "Update: Bisphosphonates" LUNAR NEWS, vol. April97, 1 April 1997 (1997-04-01), "Update: Bisphosphonates" LUNAR NEWS, vol. July96, 1 July 1996 (1996-07-01),98935752.0099829219980717Daifotis, Anastasia G.126 East Lincoln AvenueRahway, NJ 07065USSantora, Arthur C., II126 East Lincoln AvenueRahway, NJ 07065USYates, John A.126 East Lincoln AvenueRahway, NJ 07065USMerck & Co. Inc.0020047420002YCP.O. Box 2000Rahway New Jersey 07065-0900USHorgan, James Michael Fredericet al09244331Merck & Co., Inc. European Patent Department Merck Sharp & Dohme Limited, Hertford Road, HoddesdonHertfordshire, EN11 9BUGB01200703280Teva Pharmaceutical Industries Ltd.001422405 Basel Street, P.O. Box 3190Petah Tiqva 49131ILNachshen, Neil Jacobet al00085471D Young & Co 120 HolbornLondon EC1N 2DYGB02200703281Ratiopharm GbmH Ratiopharm Arzneimittel Vertriebs GmbH00197830Graf-Arco-Strasse / Albert-Schweitzer-G 3 / 3D-89079 Ulm / A-1140 ViennaDEBreuer, Markuset al09247511Breuer & Müller Partnerschaft Patentanwälte Heimeranstraße 35D-80339 MünchenDE010120070326EMerck Sharp & Dohme Manufacturing0001136096 Pitts Bay RoadPembroke HMO8BMATBECHCYDEDKESFIFRGRITLUNLPTSEATBECHCYDEDKESFIFRGRIEITLILUNLPTSEAL20030618LT20030618LV20030618MK20030618RO20030618SI2003061820021218200251